[
  {
    "ts": null,
    "headline": "AbbVie to invest $195 million in North Chicago facility that will produce active pharmaceutical ingredients",
    "summary": "Pharmaceutical company AbbVie announced Tuesday that it will construct a new $195 million facility near its headquarters in North Chicago, Illinois. AbbvVie is one of the largest biomedical companies in the world, ranking just below Pfizer in revenue. The company is known for its production of Humira, a treatment for autoimmune diseases such as rheumatoid arthritis and Crohn’s, and Botox. The ...",
    "url": "https://finnhub.io/api/news?id=745bb827fe673cde00141841e0b984a262f0952485492642e296bc0d7cabad8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755031560,
      "headline": "AbbVie to invest $195 million in North Chicago facility that will produce active pharmaceutical ingredients",
      "id": 136328255,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pharmaceutical company AbbVie announced Tuesday that it will construct a new $195 million facility near its headquarters in North Chicago, Illinois. AbbvVie is one of the largest biomedical companies in the world, ranking just below Pfizer in revenue. The company is known for its production of Humira, a treatment for autoimmune diseases such as rheumatoid arthritis and Crohn’s, and Botox. The ...",
      "url": "https://finnhub.io/api/news?id=745bb827fe673cde00141841e0b984a262f0952485492642e296bc0d7cabad8f"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks were higher late Tuesday afternoon, with the NYSE Health Care Index and the Healt",
    "url": "https://finnhub.io/api/news?id=9deb48a3b391d5a6975b76a8df57daff12c33f3652ba44ad11599bbf43d26ea9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755028431,
      "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
      "id": 136322972,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Health care stocks were higher late Tuesday afternoon, with the NYSE Health Care Index and the Healt",
      "url": "https://finnhub.io/api/news?id=9deb48a3b391d5a6975b76a8df57daff12c33f3652ba44ad11599bbf43d26ea9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.",
    "summary": "AbbVie (NYSE: ABBV) today announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the U.S. This expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. to broadly support innovation and expand critical manufacturing capabilities and capacity.",
    "url": "https://finnhub.io/api/news?id=8cd3a73855c67259ef5dc8874254c548c11d82eb287bf8354abf6cb7cac1e347",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755018000,
      "headline": "AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.",
      "id": 136320523,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the U.S. This expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. to broadly support innovation and expand critical manufacturing capabilities and capacity.",
      "url": "https://finnhub.io/api/news?id=8cd3a73855c67259ef5dc8874254c548c11d82eb287bf8354abf6cb7cac1e347"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition",
    "summary": "AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my updated look at ABBV stock prospects.",
    "url": "https://finnhub.io/api/news?id=151d83a27536563d836e2fa7e4218f8e41049a6542909e47b3015eac73d89f82",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755017964,
      "headline": "AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition",
      "id": 136322859,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196576033/image_2196576033.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my updated look at ABBV stock prospects.",
      "url": "https://finnhub.io/api/news?id=151d83a27536563d836e2fa7e4218f8e41049a6542909e47b3015eac73d89f82"
    }
  },
  {
    "ts": null,
    "headline": "MoonLake Immunotherapeutics: Maintaining A Small Holding",
    "summary": "MoonLake Immunotherapeutics remains a promising clinical-stage biotech, with potentially its first FDA approval in 2026. Click here to read why MLTX is a Hold.",
    "url": "https://finnhub.io/api/news?id=a0acb209d90dc26c4ce31ed5581f375bd750bb4043c57820c4b6e45b5b81061b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755013945,
      "headline": "MoonLake Immunotherapeutics: Maintaining A Small Holding",
      "id": 136322308,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1473708731/image_1473708731.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "MoonLake Immunotherapeutics remains a promising clinical-stage biotech, with potentially its first FDA approval in 2026. Click here to read why MLTX is a Hold.",
      "url": "https://finnhub.io/api/news?id=a0acb209d90dc26c4ce31ed5581f375bd750bb4043c57820c4b6e45b5b81061b"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet",
    "summary": "Read the latest analysis on Vertex stock and its recent earnings report here.",
    "url": "https://finnhub.io/api/news?id=457a1ccd7b4be1b5d342bea5428a17588b135225edd16dc75e6355592dcbb4c3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755009259,
      "headline": "Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet",
      "id": 136321094,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148319783/image_2148319783.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Read the latest analysis on Vertex stock and its recent earnings report here.",
      "url": "https://finnhub.io/api/news?id=457a1ccd7b4be1b5d342bea5428a17588b135225edd16dc75e6355592dcbb4c3"
    }
  },
  {
    "ts": null,
    "headline": "Starbucks upgraded, Shopify downgraded: Wall Street's top analyst calls",
    "summary": "Starbucks upgraded, Shopify downgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=f5eef989ec7c23df4c1adb50e705d4db9eb0d3d3860c33a859dfad67c86763b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755006037,
      "headline": "Starbucks upgraded, Shopify downgraded: Wall Street's top analyst calls",
      "id": 136318195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Starbucks upgraded, Shopify downgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=f5eef989ec7c23df4c1adb50e705d4db9eb0d3d3860c33a859dfad67c86763b1"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Invest $195M in New Illinois Manufacturing Plant",
    "summary": "AbbVie to Invest $195M in New Illinois Manufacturing Plant",
    "url": "https://finnhub.io/api/news?id=60db065b881bb08ece12cc0b916148a7888260498d9dbf977249f0e062a11419",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755004800,
      "headline": "AbbVie to Invest $195M in New Illinois Manufacturing Plant",
      "id": 136331283,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie to Invest $195M in New Illinois Manufacturing Plant",
      "url": "https://finnhub.io/api/news?id=60db065b881bb08ece12cc0b916148a7888260498d9dbf977249f0e062a11419"
    }
  },
  {
    "ts": null,
    "headline": "If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?",
    "summary": "AbbVie Inc. (NYSE:ABBV) is a research-driven biopharmaceutical company that discovers and delivers innovative medicines and solutions to address complex health issues. It is set to report its Q3 2025 earnings on Oct. 29. Wall Street analysts expect ...",
    "url": "https://finnhub.io/api/news?id=2dd0e3d9070d75539f87b386b034d3603e9102a352dd5ca916defe4182fda899",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755000069,
      "headline": "If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?",
      "id": 136316027,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is a research-driven biopharmaceutical company that discovers and delivers innovative medicines and solutions to address complex health issues. It is set to report its Q3 2025 earnings on Oct. 29. Wall Street analysts expect ...",
      "url": "https://finnhub.io/api/news?id=2dd0e3d9070d75539f87b386b034d3603e9102a352dd5ca916defe4182fda899"
    }
  },
  {
    "ts": null,
    "headline": "Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda",
    "summary": "The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth drivers include rising multiple myeloma cases, advances in targeted therapies like monoclonal antibodies, and the increasing adoption of immunotherapies. Enhanced diagnostics and greater healthcare accessibility are boosting market expansion. Key regions such as the U.S., Europe, and Asia-Pacific, are witnessing heightened therapy adoption. Challenges in",
    "url": "https://finnhub.io/api/news?id=935f341a4411b701496e42970e26df9cbaf2110b44122724cea5bef64808ce44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754996340,
      "headline": "Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda",
      "id": 136315997,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth drivers include rising multiple myeloma cases, advances in targeted therapies like monoclonal antibodies, and the increasing adoption of immunotherapies. Enhanced diagnostics and greater healthcare accessibility are boosting market expansion. Key regions such as the U.S., Europe, and Asia-Pacific, are witnessing heightened therapy adoption. Challenges in",
      "url": "https://finnhub.io/api/news?id=935f341a4411b701496e42970e26df9cbaf2110b44122724cea5bef64808ce44"
    }
  },
  {
    "ts": null,
    "headline": "US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche",
    "summary": "The United States Personalized Medicine Market is projected to soar to US$ 307.04 billion by 2033 from US$ 169.56 billion in 2024, experiencing a CAGR of 6.82% from 2025 to 2033. Key growth drivers include advances in next-generation sequencing, rising demand for customized treatments, and government policy support. The integration of technologies like AI and machine learning is enhancing precision in diagnostics and treatment, revolutionizing personalized healthcare. Market challenges include h",
    "url": "https://finnhub.io/api/news?id=f707ee98921e7e078140073abaf19d858e85f133b0fb14b0b53be51653626a1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754991120,
      "headline": "US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche",
      "id": 136315974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The United States Personalized Medicine Market is projected to soar to US$ 307.04 billion by 2033 from US$ 169.56 billion in 2024, experiencing a CAGR of 6.82% from 2025 to 2033. Key growth drivers include advances in next-generation sequencing, rising demand for customized treatments, and government policy support. The integration of technologies like AI and machine learning is enhancing precision in diagnostics and treatment, revolutionizing personalized healthcare. Market challenges include h",
      "url": "https://finnhub.io/api/news?id=f707ee98921e7e078140073abaf19d858e85f133b0fb14b0b53be51653626a1b"
    }
  },
  {
    "ts": null,
    "headline": "Markus Rohrwild Appointed New CEO of Gubra in a Planned Succession Process",
    "summary": "HØRSHOLM, DK / ACCESS Newswire / August 12, 2025 / Gubra (CPH:GUBRA) Following a planned succession process, the Board of Directors of Gubra has appointed Markus Rohrwild as the new CEO of the company effective September 8, 2025. Henrik Blou will ...",
    "url": "https://finnhub.io/api/news?id=a47d3ba586eaaddb62d3695940eea516161fe96d226b4b579b6227d3f4e0650a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754989200,
      "headline": "Markus Rohrwild Appointed New CEO of Gubra in a Planned Succession Process",
      "id": 136316030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "HØRSHOLM, DK / ACCESS Newswire / August 12, 2025 / Gubra (CPH:GUBRA) Following a planned succession process, the Board of Directors of Gubra has appointed Markus Rohrwild as the new CEO of the company effective September 8, 2025. Henrik Blou will ...",
      "url": "https://finnhub.io/api/news?id=a47d3ba586eaaddb62d3695940eea516161fe96d226b4b579b6227d3f4e0650a"
    }
  }
]